



Perspective

Sarcoptes-World Molecular Network (Sarcoptes-WMN): integrating research on scabies

Samer Alasaad^{a,*}, Shelley Walton^b, Luca Rossi^c, Set Bornstein^d, Marawan Abu-Madi^e,
Ramón C. Soriguer^a, Scott Fitzgerald^f, Xing-Quan Zhu^g, Werner Zimmermann^h,
Uade Samuel Ugobomoikoⁱ, Kurtis Jai-Chyi Pei^j, Jörg Heukelbach^k

on behalf of the members of the Sarcoptes-World Molecular Network

^a Estación Biológica de Doñana, CSIC, Avda América Vespucio s/n, Seville 41080, Spain

^b School of Health and Sport Sciences, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

^c Dipartimento di Produzioni Animali, Epidemiologia ed Ecologia, Università degli Studi di Torino, Grugliasco, Italy

^d Department of Virology, Immunology and Parasitology, National Veterinary Institute, Uppsala, Sweden

^e Department of Health Sciences, College of Arts and Sciences, Qatar University, Doha, Qatar

^f Diagnostic Center for Population and Animal Health, Michigan State University, Lansing, Michigan, USA

^g State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Lanzhou, Gansu Province, China

^h Fachtierarzt FVH für Schweine, Leiter der Schweineklinik der, Universität Bern, Bern, Switzerland

ⁱ Department of Zoology, Institute of Wildlife Conservation, University of Ilorin, Ilorin, Kwara State, Nigeria

^j Institute of Wildlife Conservation, National Pingtung University of Science and Technology, Neipu, Pingtung, Taiwan

^k Department of Community Health, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil

ARTICLE INFO

Article history:

Received 15 April 2010

Received in revised form 25 November 2010

Accepted 27 January 2011

Corresponding Editor: William Cameron,
Ottawa, Canada

Keywords:

Knowledge management

Sarcoptes world epidemiology

Molecular systematics

Diagnostic methods

Treatment

Control policy

SUMMARY

Parasites threaten human and animal health globally. It is estimated that more than 60% of people on planet Earth carry at least one parasite, many of them several different species. Unfortunately, parasite studies suffer from duplications and inconsistencies between different investigator groups. Hence, groups need to collaborate in an integrated manner in areas including parasite control, improved therapy strategies, diagnostic and surveillance tools, and public awareness. Parasite studies will be better served if there is coordinated management of field data and samples across multidisciplinary approach plans, among academic and non-academic organizations worldwide. In this paper we report the first 'Living organism-World Molecular Network', with the cooperation of 167 parasitologists from 88 countries on all continents. This integrative approach, the 'Sarcoptes-World Molecular Network', seeks to harmonize *Sarcoptes* epidemiology, diagnosis, treatment, and molecular studies from all over the world, with the aim of decreasing mite infestations in humans and animals.

© 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

1. The parasite and the disease

Sarcoptes scabiei causes sarcoptic mange in companion, livestock, and wild animals, as well as scabies in humans. This parasite has a very broad host range, which includes more than 100 mammalian species belonging to 27 families from 10 orders.¹ In addition to its potential to cause huge economic loss due to reduced production and increased mortality in animals,^{1–3} scabies

is an emerging/re-emerging infectious disease that threatens human and animal health globally.^{4–6} There are no accurate estimates of the prevalence of sarcoptic mange in many of the different animal populations affected worldwide. However, there are several examples of how serious an *S. scabiei* epidemic can be, causing devastating morbidity.¹

It is estimated that 300 million people are infested with scabies worldwide.^{7,8} This conservative estimate is most likely too low considering that the infection is frequently not reported in humans.⁹ The prevalence of scabies in African children can be as high as 40–80%,^{10,11} and in remote indigenous communities in northern Australia, up to 50% of children and 25% of adults were

* Corresponding author. Tel.: +34 669023392; fax: +34 954621125.
E-mail address: samer@ebd.csic.es (S. Alasaad).

found to be infested.¹² In developing countries, scabies is a significant public health problem because it is highly prevalent and complications are frequent.¹³ These may include, in the presence of bacterial superinfection, acute post-streptococcal glomerulonephritis (PSGN). Children appear to be more commonly affected by streptococcal superinfection,¹⁴ and complications such as PSGN may be fatal.¹⁵ A study performed in The Gambia showed that skin lesions associated with scabies were the leading portal of entry for organisms causing septicemia in infants aged 3 months or less.¹⁶ The presence and severity of scabies are often associated with poor living conditions and illiteracy.¹⁷ Introduction of a single case of scabies into crowded living conditions can result in an epidemic.^{18,19} The disease is also a curse in high-income countries where the prevalence may be increasing due to diagnostic failures, suspected resistance against some acaricides, and perhaps changes in social habits.²⁰

Chemotherapy of scabies is important in clinical work. Cheap, safe, and efficacious drugs are not commonly available in some of the poorer countries. Emerging drug resistance to *S. scabiei* has recently been reported from regions where previously effective acaricides have been used extensively in socially disadvantaged communities and in some developing countries.^{21–23} Researchers are addressing this in various ways, e.g., by testing (identifying) novel chemotherapeutics,^{24–26} by immunological intervention, and/or by molecular studies of the mite, including, for example, investigating whether glutathione transferases (GSTs) play any role in conferring acaricide resistance to *S. scabiei* and other mechanisms.^{27–31}

The diagnosis of *Sarcoptes* is pivotal for assessing eradication programs^{32–34} and for epidemiological studies.³⁵ For the experienced dermatologist, the clinical diagnosis of scabies may not appear difficult, but in fact scabies continues to be a diagnostic challenge³⁶ because of its diverging clinical manifestations and many differential diagnoses.²⁴ The definitive diagnosis of *Sarcoptes* infestation can be difficult as in many cases only a few mites are present on an infested host, and skin manifestations can be subtle or atypical.³⁷ There is a lack of accurate diagnostic tests for humans.^{24,38} In addition, for many domestic and wild animals, including threatened species such as Chamois and Gorillas,^{39,40} better specific *Sarcoptes* diagnostic methods need to be developed.

For many years, parasitologists have been immersed in an ongoing debate as to “whether or not *S. scabiei* infecting different hosts belong to different species or sub-species, or whether they are, in fact, monospecific”.⁴ Today, the species *Sarcoptes scabiei* is divided into varieties based on the host species, e.g., *S. scabiei* var. *hominis* and *S. scabiei* var. *canis*. Humans can be infested with animal varieties, but in this case the disease is usually limited to certain topographic sites and is self-limited. It has been shown that an epidemiological relationship does not exist between sarcoptic mange foci,⁴¹ while morphological studies have failed to identify any significant differences between populations of mites.⁴² Experimental cross-contamination of hosts with some different *S. scabiei* varieties is commonly unsuccessful,⁴³ however, cross-transmission/infection is common in some varieties, e.g., *S. scabiei* var. *vulpes/canis* readily infect dogs and other canids as well as felids, including domestic European cats.² In addition, this variety of *S. scabiei* also readily infects/infests humans causing pseudo-scabies.² Research into finding an answer to the question of whether or not *S. scabiei* is a single species and understanding the ‘host-specificity’ of the mite has advanced in the last decade with the advent of polymerase chain reaction (PCR) technology and molecular marker systems in the genetic era. Molecular studies based on short fragments of mitochondrial or ribosomal DNA spacer regions failed to identify *S. scabiei* populations to the host species level and geographical localities.^{42,44–47} Studies on a

central fragment of the 16S gene and the complete cytochrome c oxidase subunit I gene (COI) in combination with microsatellite markers provided some support for a genetic differentiation of *S. scabiei*. These genetic markers demonstrated significant relationships between *S. scabiei* mitochondrial DNA (mtDNA) haplotypes and microsatellite allele frequencies, and host species and geographical locations, even at skin-scale level.^{48–50} Immunological studies have shown that each variety of *S. scabiei* tested produces a range of proteins, both variety-specific and immunologically identical and shared by the different mite sub-types.⁵¹

Clinical manifestations of scabies range from singular nodules to severe crusted scabies. The underlying causes for these different manifestations may be found in the immunological host response, but are not fully understood.

In summary, there is ongoing debate about the host specificity and range of different *Sarcoptes* populations on a worldwide scale. The taxonomical status of this important parasite remains unclear. Sensitive diagnostic methods are still not available for many host species, including humans, and new therapeutic options need to be evaluated. Therefore, well-designed studies aimed at better understanding the world epidemiology and transmission dynamics, and the design and development of sensitive and specific diagnostic methods are of paramount importance.

2. *Sarcoptes*-World Molecular Network initiative

During the last few years we have been working on *Sarcoptes* mite epidemiology, diagnosis, treatment, control, clinical aspects, and genetics, and we are in touch with colleagues who are working on *Sarcoptes* mite epidemiology and control worldwide. This has enabled us to create the ‘*Sarcoptes*-World Molecular Network’ (WMN), which currently includes 167 parasitologists from 88 countries from all continents. The *Sarcoptes*-WMN aims to be a facilitator of collaborative, mainly molecular research on *Sarcoptes*. The network will bring together a wide spectrum of research communities, aiming to share information, expertise, samples, and infrastructure. The *Sarcoptes*-WMN includes different institutions such as universities, hospitals, centers of animal health, medical colleges, public health institutes, private clinics, medical centers, biological institutes, veterinary research laboratories, animal health services, clinical research centers, public health institutes, and wildlife conservation institutes worldwide.

3. Overall strategy of the *Sarcoptes*-World Molecular Network

The *Sarcoptes*-WMN plans to ‘pump-prime’ a new genetic era of research into this important parasite, with the aim of achieving the following:

1. Technology and knowledge transfer among specialists and human and veterinary practitioners all over the world on the diagnosis, epidemiology, and management of *Sarcoptes scabiei* infestations. This will prevent *Sarcoptes* research duplication and foster protocol uniformity, which would fast-track world research on *Sarcoptes*.
2. Increase knowledge on the world epidemiology of this ubiquitous parasite.
3. The design and development of universal and specific *Sarcoptes* PCR-based and antibody-based diagnostic methods.
4. Create a global open access ‘*Sarcoptes*-Specimens World Bank’.
5. Create a global open access ‘*Sarcoptes*-gDNA World Bank’.
6. Create a global open access database on the world molecular systematics of the species *Sarcoptes*, inferred from molecular marker data from thousands of individual *Sarcoptes* specimens worldwide.

7. Examine the long-term evolutionary history undergone by this ectoparasite, and establish a possible scenario for *Sarcoptes* migration throughout the world.
8. Formulate public and animal health control policies with the aim of decreasing *S. scabiei* infections in humans and in animals.

4. Conclusions

The concept of 'network' plays a central role in all branches of our life. In the area of parasitology research, it is crucial to realize the importance of standardizing research protocols worldwide. Availability of biological samples is a recognized limiting factor for biological and genetic studies; hence the creation of a global open access 'Living organism-Specimens/gDNA World Bank' is of pivotal interest. Sufficiently robust and well-standardized diagnostic methods are needed in the form of ready-to-use kits in the routine laboratory for many host-derived parasite species. The accurate estimation of parasite host specificity and range will only be achieved by global epidemiology and molecular studies.

Sarcoptes-WMN is just starting its operations in terms of technology and knowledge transfer among its members, *Sarcoptes* specimen collection, and the design of the epidemiological/molecular studies. We are aware that such a world genetic epidemiology study in different host species, countries, and geographical areas requires wider awareness and collaborations from all sectors concerned in animal/human welfare, and especially from those interested in the disease.

To our knowledge this is the first world molecular network, which we hope will serve as a framework around which further 'Living being-World Molecular Networks' (Anima-WMN) will be constructed.

Acknowledgements

We acknowledge the members of the *Sarcoptes*-World Molecular Network: Abdulrazak Abyad, Afonso Almeida, Alasdair Nisbet, Aleksandar M. Dzamic, Alemayehu Regassa, Alvaro Oleaga, Aly Raza, Angelica Terashima, Anna Rita Molinar Min, Antonio Sánchez Baca, Apolinario A. Alicante, Arlo Upton, Asoke K. Basu, Baik Kee Cho, Baswaid Saeed Haj, Ben-Sari Charaf, Bett Bernard, Brian Lassen, Carl Soulsbury, Christian Gortazar, Christian Raccurt, Citterio Carlo, Claire Lacroix, Clément Kerah Hinzoumbé, Craig G. Burkhart, Dalmiro Cazorla, Diana Zele, Djohan Vincent, Dominga Soglia, Dumitru Catalin Acatrinei, Eduardo Gotuzzo, Edward Omudu, Elias Papadopoulos, Elzbieta Zbikowska, Emmanuel Swai, Emmanuel Serrano, Enala Mwase, Eva Molin, Evi Jean Bedel, Fabien Hountondji, Farhana Riaz Chaudhry, Faten Al-Braikan, Francis Gakuya, Galina Efremova, Golamreza Molavi, Gorazd Vengust, Guangyou Yang, Habibah Arshad, Hamza Babiker, Han Jianlin, Harold van der Heijden, Harrat Zoubir, Hayder Ahmed Giha Mohammed, Hetron M Munang'andu, Hiroyoshi Ninomiya, Ifor Owen, Issiaka Soulama, Jacqueline Lusat, Janet Wilson, Javier Millán Gasca, Jesús M. Pérez, Jong-Yil Chai, Jorg Heukelbach, Jorge E. Zavala Castro, José Enrique Granado, Josephus J. Fourie, Juanita Trejos-Suárez, Kamal Rai, Karla Georges, Kazi Selim Anwar, Khalid Hameed, Khalid Khallaanyoune, Kosta Y. Mumcuoglu, Krzysztof Solarz, Kurtis Jai-Chyi Pei, Landry Riba Mandicó, Lazăr Mircea, Leon Fourie, Liana de Moura Ariza, Lisette Kohagne Tongué, Liviu Miron, Loan Towersey, Michael Löwenstein, Luca Rossi, Luís Miguel Rosalino, Luisa Rambozzi, Malyarchuk Alexander, Manolis Saridomichelakis, Marawan Abu-Madi, Marcela Lareschi, Marek Asman, Mari Heinonen, Mariana Ahmad, Mario Baldi, Mark Strong, Mathieu Sarasa, Mavoungou J. François, Mbaye Mbengue, Mirgani Ali Alhag, Mohamed A. Gebely, Mohamed E.

Hamid, Mohamed Gharbi, Mohammad Y. Halami, Natividad Hernández, Noel Ndeledje Gondje, Olga V. Morozova, Olger Calderón-Arguedas, Omar Hamarsheh, Osman Selçuk Aldemir, Pablo Díez Baños, Paola Sacchi, Patrocínio Morrondo, Piotr Cuber, Rachael Collins, Rajender Kumar, Ramgopal Laha, Ramón C. Soriguer, Rehana A. Sani, Rhonda Pinckney, Riccardo Orusa, Richard Maude, Roberto Rasero, Rod Hay, Rodrigo Rosario-Cruz, Rolf K. Schuster, Sadegh Rahbari, Saeed A. Ba-Angood, Said Amer, Samar Al Nahhas, Samer Alasaad, Samia Boussaa, Samuel Uade, Sandra Maione, Sanjay Kumar, Santiago Lavín, S.C. Yadav, Scott Fitzgerald, Sergio Vañó Galván, Set Bornstein, Shelley Walton, Shumaila Naz, Sokolova Tatyana, Soloherilala Raharimanana, Sorin Pasca, Stefano Sartore, Steffen Rehbein, Steve Harris, Sunil Kumar Joshi, Syed Afzalul Karim, Tatyana Stetanovska, Thaer Douri, Thomas Geurden, Toby Leslie, Toku Yanai, Tonay Inceboz, Ulrich Hengge, Valeria Sabaj, Veronica Spalenza, Wafa Al-Kandari, Windell L. Rivera, Xing Quan Zhu, Yaxsier de Armas Rodríguez, Yaya Ibrahim Coulibaly, Yee Yee Mya, Yuliya V. Lopatina, Zuhair Bani Ismail, Werner Zimmermann.

Conflict of interest: No conflict of interest to declare.

References

1. Bornstein S, Mörner T, Samuel WM. *Sarcoptes scabiei* and sarcoptic mange. In: Samuel WM, Pybus MJ, Kocan AA, editors. *Parasitic diseases of wild mammals*. Second ed., Ames, Iowa: Iowa State University Press; 2001 p. 107–19.
2. Bornstein S. *Sarcoptes scabiei* infections of the domestic dog, red fox and pig. PhD thesis. Uppsala, Sweden: Department of Veterinary Microbiology, Section of Parasitology, Swedish University of Agricultural Sciences and National Veterinary Institute; 1995.
3. Dagleish MP, Ali Q, Powell RK, Butz D, Woodford MH. Fatal *Sarcoptes scabiei* infection of blue sheep (*Pseudois nayaur*) in Pakistan. *J Wildl Dis* 2007;**43**:512–7.
4. Daszak P, Cunningham AA, Hyatt AD. Emerging infectious diseases of wildlife: global threats to biodiversity and human health. *Science* 2000;**287**:443–9.
5. Fthenakis GC, Papadopoulos E, Himonas C, Leontides L, Kritas S, Papatsas J. Efficacy of moxidectin against sarcoptic mange and effects on milk yield of ewes and growth of lambs. *Vet Parasitol* 2000;**87**:207–16.
6. Fthenakis GC, Karagiannidis A, Alexopoulos C, Brozos C, Papadopoulos E. Effects of sarcoptic mange on the reproductive performance of ewes and transmission of *Sarcoptes scabiei* to newborn lambs. *Vet Parasitol* 2001;**95**:63–71.
7. Kumaresan J, Sathiakumar N. Climate change and its potential impact on health: a call for integrated action. *Bull World Health Organ* 2010;**88**:163.
8. Alexander JO. Arthropods and human skin. Berlin: Springer; 1984.
9. Christophersen J. The epidemiology of scabies in Denmark 1900–1975. *Arch Dermatol* 1986;**114**:747–50.
10. Kristensen JK. Scabies and pyoderma in Lilongwe, Malawi. Prevalence and seasonal fluctuation. *Int J Dermatol* 1991;**30**:699–702.
11. Terry BC, Kanjah F, Sahr F, Korteque S, Dukuly I, Gbakima AA. *Sarcoptes scabiei* infestation among children in a displacement camp in Sierra Leone. *Public Health* 2001;**115**:208–11.
12. Carapetis JR, Connors C, Yarmirr D, Krause V, Currie BJ. Success of a scabies control program in an Australian aboriginal community. *Pediatr Infect Dis J* 1997;**16**:494–9.
13. Heukelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbidity of scabies and pediculosis capitis in resource-poor communities in Brazil. *Br J Dermatol* 2005;**153**:150–6.
14. Carapetis JR. The current evidence for the burden of group A streptococcal diseases. Geneva, Switzerland: World Health Organization; March 2, 2004. WHO/FCH/CAH/05.07.
15. McCarthy JS, Kemp DJ, Walton SF, Currie BJ. Scabies: more than just an irritation. *Postgrad Med J* 2004;**80**:382–7.
16. Mulholland EK, Ogunlesi OO, Adegbola RA, Weber M, Sam BE, Palmer A. Etiology of serious infections in young Gambian infants. *Pediatr Infect Dis J* 1999;**18**:35–41.
17. Feldmeier H, Jackson A, Ariza L, Lins Calheiros CM, Soares VL, Oliveira FA, et al. The epidemiology of scabies in an impoverished community in rural Brazil: presence and severity of disease are associated with poor living conditions and illiteracy. *J Am Acad Dermatol* 2009;**60**:436–43.
18. Andersen BM, Haugen H, Rasch M, Heldal Haugen A, Tageson A. Outbreak of scabies in Norwegian nursing homes and home care patients: control and prevention. *J Hosp Infect* 2000;**45**:160–4.
19. Obasanjo OO, Wu P, Conlon M, Karanfil LV, Pryor P, Moler G, et al. An outbreak of scabies in a teaching hospital: lessons learned. *Infect Control Hosp Epidemiol* 2001;**22**:13–8.
20. Lindh J, Persson LM. Allt fler fall av skabb (Increasing cases of scabies). *Smittskydd* 2009;**4**:22–3.
21. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in *Sarcoptes scabiei*. *Clin Infect Dis* 2004;**39**:8–12.

22. Bradberry SM, Cage SA, Proudfoot AT, Vale JA. Poisoning due to pyrethroids. *Toxicol Rev* 2005;**24**:93–106.
23. Sanderson H, Laird B, Pope L, Brain R, Wilson C, Johnson D, et al. Assessment of the environmental fate and effects of ivermectin in aquatic mesocosms. *Aquat Toxicol* 2007;**85**:229–40.
24. Heukelbach J, Feldmeier H. Scabies. *Lancet* 2006;**367**:1767–74.
25. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. *Bull World Health Organ* 2005;**83**:34–42.
26. Heukelbach J, Winter B, Wilcke T, Muehlen M, Albrecht S, de Oliveira FA, et al. Selective mass treatment with ivermectin to control intestinal helminthiasis and parasitic skin diseases in a severely affected population. *Bull World Health Organ* 2004;**82**:563–71.
27. Holt DC, Fischer K, Allen GE, Wilson D, Wilson P, Slade R, et al. Mechanisms for a novel immune evasion strategy in the scabies mite *Sarcoptes scabiei*: a multi-gene family of inactivated serine proteases. *J Invest Dermatol* 2003;**121**:1419–24.
28. Pasay C, Arlian L, Morgan M, Vyszynski-Moher D, Rose A, Holt D, et al. High-resolution melt analysis for the detection of a mutation associated with permethrin resistance in a population of scabies mites. *Med Vet Entomol* 2008;**22**:82–8.
29. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. *Future Microbiol* 2008;**3**:57–66.
30. Molin EU. In vitro characterization of glutathione transferases from *Sarcoptes scabiei*. Doctoral thesis No. 2009;80. Uppsala, Sweden: Swedish University of Agricultural Sciences; 2009.
31. Mounsey KE, Pasay CJ, Arlian L, Morgan MS, Holt DC, Currie BJ, et al. Increased transcription of glutathione S-transferases in acaricide exposed scabiei mites. *Parasit Vectors* 2010;**3**:43.
32. Jacobson M, Bornstein S, Wallgren P. The efficacy of simplified eradication strategies against sarcoptic mange mite infections in swine herds monitored by an ELISA. *Vet Parasitol* 1997;**81**:249–58.
33. Jacobson M, Bornstein S, Palmer E, Wallgren P. Elimination of *Sarcoptes scabiei* in pig herds by single and double administrations of an avermectin. *Acta Vet Scand* 2000;**41**:227–35.
34. Heinonen M, Bornstein S, Kolhinen R, Saloniemi H, Tuovinen V. Eradication of porcine sarcoptic mange within a health declared production model. *Acta Vet Scand* 2000;**41**:41–50.
35. Wallgren P, Bornstein S. The spread of porcine sarcoptic mange during the fattening period revealed by the development of antibodies to *Sarcoptes scabiei*. *Vet Parasitol* 1997;**73**:315–24.
36. Walton SF, Currie BJ. Problems in diagnosing scabies, a global disease in human and animal populations. *Clin Microbiol Rev* 2007;**20**:268–79.
37. Mellanby K. The development of symptoms, parasitic infection and immunity in human scabies. *Parasitology* 1944;**35**:197–206.
38. Haas N, Wagemann B, Hermes B, Henz BM, Heile C, Schein E. Crossreacting IgG antibodies against fox mite antigens in human scabies. *Arch Dermatol Res* 2005;**296**:327–31.
39. Rambozzi L, Menzano A, Lavin S, Rossi L. Biotin–avidin amplified ELISA for detection of antibodies to *Sarcoptes scabiei* in chamois (*Rupicapra spp.*). *Vet Res* 2004;**35**:701–8.
40. Graczyk TK, Mudakikwa AB, Cranfield MR, Eilenberger U. Hyperkeratotic mange caused by *Sarcoptes scabiei* (Acariformes: Sarcoptidae) in juvenile human-habituated mountain gorillas (*Gorilla gorilla beringei*). *Parasitol Res* 2001;**87**:1024–8.
41. Berrilli F, D'Amelio S, Rossi L. Ribosomal and mitochondrial DNA sequence variation in *Sarcoptes* mites from different hosts and geographical regions. *Parasitol Res* 2002;**88**:772–7.
42. Fain A. Epidemiological problems of scabies. *Int J Dermatol* 1978;**17**:20–30.
43. Arlian LG. Biology, host relations, and epidemiology of *Sarcoptes scabiei*. *Ann Rev Entomol* 1989;**34**:139–61.
44. Zahler M, Essig A, Gothe R, Rinder H. Molecular analyses suggest monospecificity of the genus *Sarcoptes* (Acariformes: Sarcoptidae). *Int J Parasitol* 1999;**29**:759–66.
45. Skerratt LF, Campbell NJ, Murrell A, Walton S, Kemp D, Barker SC. The mitochondrial 12S gene is a suitable marker of populations of *Sarcoptes scabiei* from wombats, dogs and humans in Australia. *Parasitol Res* 2002;**88**:376–9.
46. Gu XB, Yang GY. A study on the genetic relationship of mites in the genus *Sarcoptes* (Acariformes: Sarcoptidae) in China. *Int J Acarol* 2008;**32**:183–90.
47. Alasaad S, Soglia D, Spalenza V, Maione S, Soriguer RC, Pérez JM, et al. Is ITS-2 rDNA suitable marker for genetic characterization of *Sarcoptes* mites from different wild animals in different geographic areas? *Vet Parasitol* 2009;**159**:181–5.
48. Walton SF, Choy JL, Bonson A, Vale A, McBroom J, Taplin D, et al. Genetically distinct dog-derived and human-derived *Sarcoptes scabiei* in scabies endemic communities in northern Australia. *Am J Trop Med Hyg* 1999;**61**:542–7.
49. Walton SF, Dougall A, Pizzutto S, Holt D, Taplin D, Arlian LG, et al. Genetic epidemiology of *Sarcoptes scabiei* (Acariformes: Sarcoptidae) in northern Australia. *Int J Parasitol* 2004;**34**:839–49.
50. Alasaad S, Soglia D, Sarasa M, Soriguer RC, Pérez JM, Granados JE, et al. Skin-scale genetic structure of *Sarcoptes scabiei* populations from individual hosts: empirical evidence from Iberian ibex-derived mites. *Parasitol Res* 2008;**104**:101–5.
51. Arlian LG, Morgan MS, Arends LL. Immunologic cross-reactivity among various strains of *Sarcoptes scabiei*. *J Parasitol* 1996;**82**:66–72.